RXi Pharmaceuticals to Deliver Presentations at Upcoming Conferences Outlining the Development and Progression of its Next Generation rxRNA? Therapeutic Platform

WORCESTER, Mass.--(BUSINESS WIRE)--Apr 23, 2010 - RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi), today announced that senior members of its management will be presenting at upcoming conferences and will highlight critical aspects of the development of RXi's next generation rxRNA™ therapeutic platform as well as specific preclinical data generated with this platform.

Drs. Joanne Kamens, Dmitry Samarsky and Pamela Pavco will be speaking at the IBC TIDES Oligonucleotide and Peptide® Technology and Product Development Conference and the IBC Oligonucleotide Therapeutics Discovery Conference co-located in Boston, Massachusetts on April 25 - 28, 2010. Their presentations will focus on key topics related to the company's therapeutic platform, highlighting the following: a) Critical strategies for design of oligonucleotide compounds with therapeutic potential; b) Development and composition of RXi's novel RNAi compounds including single-oligo (rxRNAsolo™) and ˜self-delivering' rxRNA (sd-rxRNA™) molecules; and c) In vivo activity of RXi's proprietary sd-rxRNA compounds, which silence targets in vitro and in vivo with no additional delivery vehicle.

Next generation rxRNA™ compounds potentially convey significant advantages over conventional siRNA (“small interfering RNA”) compounds, and offer many of the properties that may be important to the clinical development of RNAi-based drugs, including high potency, increased resistance to nucleases, a reduction in off-target effects, and, in the case of the sd-rxRNA compounds, access to cells and tissues with no requirement for additional delivery vehicles. In addition, the enhanced drug-like properties engineered into the sd-rxRNA configuration afford opportunities for use in a broad array of therapeutic indications making this new class of RNAi molecules a key addition to the rxRNA family of compounds.

The conference presentations by management include the following:

Sunday, April 25, workshop at 2:00 PM

 

  • Joanne Kamens, Ph.D., Senior Director of Research Collaboration Management, will participate in a workshop entitled “Oligonucleotide Lead Discovery and Candidate Selection” and will outline strategies for high throughput identification of advanced rxRNA compounds for therapeutic programs Her presentation is entitled “Design of Oligonucleotide Screens: Using Early Design Parameters to Increase Success.”

Monday, April 26, 2:45 PM

 

  • Dmitry Samarsky, Ph.D., Vice President of Technology Development, will deliver a presentation entitled “Combination of Oligo Configuration and Chemical Modification Provides Drug-Like Properties to RNAi Molecules.” His talk will outline the development of novel therapeutic chemistries and configurations of RNAi triggers, with a focus on sd-rxRNAs, and the optimization of this technology to enable in vivo studies.

Wednesday, April 28, 8:45 AM

 

  • Pamela Pavco, Ph.D., Vice President of Drug Development will present a talk entitled “Optimization of RNAi for Therapeutic Development,” highlighting the ability of sd-rxRNAs to affect robust in vivo gene silencing upon local administration to the skin using intradermal administration. Results presented support the use of sd-rxRNAs for clinical applications where direct administration to the tissue of interest is possible.

About RNA Interference (RNAi) and Self-delivering rxRNA™ (sd-rxRNA™)

Regarded as a revolutionary discovery in biology, RNA interference (RNAi) is a naturally occurring mechanism whereby short, double-stranded RNA molecules interfere with the expression of genes in living cells. This mechanism has the potential to be harnessed to "silence" or specifically block the production of disease-causing proteins before they are made. This technology can potentially be used to treat human diseases by "turning-off" genes that lead to disease in the first place. RXi Pharmaceuticals is using RNAi technology to develop RNA-derived molecules targeting disease-causing genes.

Self-delivering rxRNA (sd-rxRNA) is a proprietary technology developed at RXi which has the potential to enable the efficient delivery of RNAi compounds without the requirement of an additional delivery vehicle. This novel property has the potential to enable development of sd-rxRNA compounds for therapeutic use in a wide variety of disease indications.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals is a discovery-stage biopharmaceutical company pursuing the development and commercialization of proprietary therapeutics based on RNA interference (RNAi) for the treatment of human diseases. RXi has a comprehensive therapeutic platform that includes both novel RNAi compounds and advanced delivery methods that can potentially be applied for local and systemic applications, against targets that may be undruggable by other modalities. RXi uses its proprietary version of RNAi compounds -- rxRNA™ -- that provide an advanced alternative to conventional small interfering RNAs (siRNAs) and define the next generation of RNAi technology. These include rxRNAori™, rxRNAsolo™, and sd-rxRNA™ (or “self delivering” RNA), which are distinct from, and potentially convey significant advantages over, classic siRNAs. RXi Pharmaceuticals believes it is well positioned to compete successfully in the RNAi-based therapeutics market with its accomplished scientific advisors, including Dr. Craig Mello, recipient of the 2006 Nobel Prize for his co-discovery of RNAi; a management team that is experienced in developing RNAi products; and a strong and early, but broad, intellectual property position in RNAi chemistry and delivery. www.rxipharma.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about future expectations, plan and future development of RXi Pharmaceutical Corporation's products and technologies. These forward-looking statements about future expectations, plans and prospects of the development of RXi Pharmaceutical Corporation's products and technologies involve significant risks, uncertainties and assumptions, including the risk that the development of our RNAi-based therapeutics may be delayed or may not proceed as planned and we may not be able to complete development of any RNAi-based product, the risk that the FDA approval process may be delayed for any drugs that we develop, risks related to development and commercialization of products by our competitors, risks related to our ability to control the timing and terms of collaborations with third parties and the possibility that other companies or organizations may assert patent rights that prevent us from developing our products. Actual results may differ materially from those contemplated by these forward-looking statements. RXi Pharmaceuticals Corporation does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release.

 

Contact: RXi Pharmaceuticals
Investor Relations
508-929-3615
ir@rxipharma.com
or
Investors
S. A. Noonan Communications
Susan Noonan
212-966-3650
susan@sanoonan.com
or
Media
Rx Communications Group
Eric Goldman
917-322-2563
egoldman@rxir.com

 

 

Posted: April 2010

View comments

Hide
(web4)